Lilly as an employment destination
Eli Lilly and Co. has experienced a string of setbacks in recent years. Is it still a good place to work?
Eli Lilly and Co.
Articles
Lilly reorganization to cut 5,500 positions over 2 years
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Study weakens Lilly’s fight against price controls
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
Lilly paid doctors to prescribe Zyprexa, notes say
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers’ program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
Lilly spent $3.6M on lobbying in second quarter
Drugmaker Eli Lilly and Co. spent nearly $3.6 million in the second quarter lobbying the federal government on health care
reform and trademark issues, among other topics, according to a recent disclosure form.
Lilly stock slips after analyst downgrade
The price of Eli Lilly and Co.’s stock veered lower this morning after a Goldman Sachs analyst downgraded her rating from
neutral to sell.
Lilly drops osteoporosis pipeline drug
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.
Lilly pays $224,000 to area doctors
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But
Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first
quarter.
Glut of downtown office space grows
Safeco is leaving a five-building complex on North Meridian Street, and Eli Lilly and Co. has offered for lease its entire
four-building Faris campus.
Abatement approval paves way for Covance jobs
The Hancock County Council this morning unanimously approved a tax-incentive agreement that should lead Covance Inc. to add
315 jobs at its Greenfield Laboratories.
Lilly reorganizes venture capital unit
Eli Lilly and Co. has reorganized its venture capital division and simultaneously poured in an additional $25 million.
Lilly offering buyouts to 4,000 sales reps
Indianapolis-based Eli Lilly and Co. today said it is offering buyouts to its U.S. sales force,
with hopes of trimming about 300 sales representatives before a sales restructuring set to begin in January, Reuters reported.
Lilly software spinoff Maaguzi sells for $11 million
Investors in a company built around clinical research software bought from Eli Lilly and Co. have found their exit, though
it’s far from the lucrative payoff they’d once imagined.
Lilly’s Effient launch just one of its many challenges
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Eli Lilly CEO, wife give United Way $1M gift
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total
of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
Eli Lilly CEO, wife give United Way $1M gift
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way
of Central Indiana a total of $1 million over the next four years as a “challenge to CEOs and other community leaders to step
up their giving.”
Lilly cancels trials for experimental MS drug
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
BREAKING: FDA approves Lilly blood-thinner prasugrel
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Lilly asks FDA to review weekly diabetes drug
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Lilly cancer drug OK’d for new use
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.